Biogen Idec's (NASDAQ:BIIB) latest earnings report is the envy of the industry as Tecfidera keeps marching toward its multi-billion dollar potential. Beyond multiple sclerosis collaboration revenue from Roche's best-selling cancer therapy Rituxan continues to fill Biogen's coffers, and a recent approval opened the door to the $6 billion hemophilia A market.
Of course, these gains come at a price. Analysts have been rightfully concerned that Tecfidera might cannibalize previous MS blockbusters. Also, gaining market share in an increasingly crowded hemophilia space isn't going to be easy. Watch the slideshow below to see whether or not these concerns are materializing.
Leaked: This coming blockbuster will even make Biogen Idec jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.